Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$386.00K$386.00K−50.4% vs Q2 2019 Net Income-$6.52M-$6.52MN/M vs Q2 2019 EPS Diluted-$0.04-$0.04N/M vs Q2 2019 Gross Profit$311,000−53.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,239,000N/M Free Cash Flowderived-$4,245,000N/M Margins · derivedGross margin80.6%−5.7 pt vs Q2 2019
Operating margin-1658.5%−269.5 pt vs Q2 2019
Net margin-1689.6%+2165.6 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 6, 2020 · 37 d after period end